BioScreening - organic compounds for screening

08.07.2010 Optimer Pharmaceuticals Receives Milestone Payment From Cempra for Next-Generation Macrolide Antibiotic
Optimer Pharmaceuticals, Inc. today announced it has received a $500,000 milestone payment from Cempra Pharmaceuticals, Inc. pursuant to the terms of a licensing agreement between the companies. The milestone payment was made as a result of Cempra’s continuing development of a next-generation macrolide (CEM-101) for the treatment of respiratory […]
More bioscreening news...

08.07.2010 Ranbaxy to transfer drug discovery unit to Daiichi Sankyo
Daiichi Sankyo and Ranbaxy Laboratories, a research based pharmaceutical company, have announced that Ranbaxy’s new drug discovery research, or NDDR, has been transferred to Daiichi Sankyo India Pharma as part of the strategy to strengthen the global R&D structure of the Daiichi Sankyo Group. The transaction has been reportedly approved […]
More bioscreening news...

08.07.2010 Sanford-Burnham robots speed up path to discovery
The work force at Lake Nona’s Sanford- Burnham Institute includes 90 scientific staffers, 60 administrators and support personnel — and a team of three robots. The robots are part of a $15 million investment from the National Institutes of Health and occupy a large, glass-enclosed room on the bottom floor of Burnham’s Lake Nona campus. Although […]
More bioscreening news...

08.07.2010 Molecular Templates and ImClone Systems Form Oncology Drug Discovery and Translation Research Collaboration
Molecular Templates announced today that it has entered into a collaborative oncology drug discovery and translation research agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Under the terms of the […]
More bioscreening news...

08.07.2010 TimTec launches a new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services.
TimTec launched a new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services. The emergence of the division is an evolutionally progression for TimTecs business development. The company has been known for its expertise in organic chemistry design and supply for drug discovery for 15 years. TimTec scientists have a proven track record of providing high quality services and showing outstanding integrity to their clients.
More bioscreening news...

27.07.2010 Nine U.S. Health Research Centers to Receive $255 Million
Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes of Health.
More bioscreening news...

27.07.2010 BioFocus and University of Bristol enter drug discovery collaboration in chronic pain
Saffron Walden and Bristol, UK; 16 July 2010 BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total contract value for BioFocus could exceed 3.3 million in research fees over two years.
More bioscreening news...

27.07.2010 Aquapharm and AMRI Enter into a Novel Marine Chemistry Collaborationa
Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.Under the terms of this agreement, drawing on its substantial experience and expertise from previous screening campaigns with its terrestrial natural products library, AMRI will screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target and will isolate and elucidate the structures of novel hits. Aquapharm retains all rights to compounds resulting from the collaboration.
More bioscreening news...

new | june 2010 | october 2009 | may 2009 | january 2009 | october 2008 | april 2008 | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003